Annual Report 2021/2022
- Published: 20 December 2022
- Version: V1.0
- 29 min read
Introduction
Welcome to the NIHR annual report covering the period April 2021 to March 2022. This is my first annual report since being appointed Chief Scientific Adviser for the Department of Health and Social Care (DHSC) and Chief Executive of NIHR in August 2021.
This year has been a year of transition. It began in a COVID-19-enforced lockdown when the pandemic was the focus of much of NIHR’s work and attention and the vaccination programme that we were central to developing was well underway. As the months passed, we gradually returned to supporting a more balanced portfolio of research. Over the year, COVID-19 evolved from being an emergency priority to settling as a ‘constant’ consideration in our mission to improve the health and wealth of the nation through research.
In June 2021, we published Best Research for Best Health: The Next Chapter which sets out our priorities now and into the future. In this document, we identify seven ‘areas of strategic focus’ – areas where we need to work with urgency and in fundamentally different ways if we are to address the changing needs of people and communities in the 21st century. All support NIHR’s commitment to addressing health inequalities.
One of our areas of strategic focus is embedding equality, diversity and inclusion across NIHR’s research, systems and culture. This is to ensure that our research reflects the diversity of the UK population leading to better health outcomes and more value for money through higher economic returns to research. In August we instigated a three-month self-assessment of how race equality is delivered in health research, working in partnership with local government, higher education, the NHS, and the life sciences and third sectors. At the same time, we collated and published our first set of annual diversity data for funding programmes, which will provide a vital benchmark to monitor our progress in EDI over time.
In line with the Government’s commitment to Open Access, we published a new Open Access policy for NIHR-funded researchers in November. All peer-reviewed research articles arising from NIHR-funded research studies will now be immediately available under an open licence. Following this, we worked with stakeholders to develop resources to support implementation, which we released in March. Resources included step-by-step policy guidance and a short checklist quickly summarising how to comply with the policy.
Our portfolio remains aligned with the UN Sustainable Development Goals, and during this year we increased our commitment to promoting universal health coverage and contributing towards addressing the emerging health challenges of climate change. In November, at the UN Climate Change Conference (COP26) in Glasgow, I announced a new package of funding for research into climate and health. It included a £20 million funding call to develop new evidence to improve the health outcomes of people most affected by climate change and extreme weather events in low and middle-income countries. Four months later, we launched major research calls into delivering more sustainable health and care systems at home and abroad.
Our year of transition was highlighted by key appointments and recognitions. At the same time as I was appointed to my role, Professor Waljit Dhillo was appointed to the role of Dean of the NIHR Academy. As Dean, he supports the delivery and development of NIHR research training programmes, ensuring they meet the needs of the current research landscape. He also ensures that NIHR’s strategy addresses equality, diversity and inclusion across all academic and research capacity programmes, schemes and initiatives.
During the year, it was wonderful to see many NIHR leaders being awarded honours. Dr Jonathan Sheffield, former Chief Executive of the NIHR’s Clinical Research Network, and Professor Nick Lemoine, Medical Director of the Network, both received CBEs for services to medical/ clinical research, particularly during the COVID-19 pandemic. Professor Kamlesh Khunti, Director of NIHR’s Applied Research Collaborations in the East Midlands, received a CBE for services to health, and Professor Martin Knapp, Director of the NIHR School for Social Care Research, received a CBE for services to social care research. I was also pleased to note that a number of other leaders were awarded an OBE or MBE.
Towards the end of the year, we decided to change the name of the NIHR to the ‘National Institute for Health and Care Research’ with effect from the beginning of April 2022. Since its establishment in 2006, the NIHR has invested over £200m in more than 470 social care research projects, with £90m worth of NIHR-funded social care studies starting in the last three years. We are committed to both deepening and broadening the range of social care we support - through funding a range of projects, building capacity within our research delivery infrastructure, strengthening the links between academia and practice, and engaging carers and people who need care and support.
In this report, we have showcased some of the work that we have undertaken, highlighted through our six core workstreams. Over the year, NIHR had a positive impact on government policy and on health and social care practice in numerous areas, some of which are highlighted in this report; you can learn more about our impact and stay up to date with NIHR news through our social media channels.
Professor Lucy Chappell
Chief Scientific Advisor, DHSC
Chief Executive of NIHR
Investing in world-class expertise, facilities and a skilled delivery workforce, to translate discoveries into improved treatments and services
Our infrastructure supports the research we fund and underpins research funded by others, transforming the health system’s ability to turn scientific discoveries into new or improved treatments and services. The widespread, national uptake of these innovations is enabled by applied research studies delivered through this infrastructure.
NIHR launches a new funding competition to drive innovation in health research
In April 2021, NIHR launched a new competition to fund research to translate lab-based discoveries into new treatments, diagnostics and medical technologies for patients. The new NIHR Biomedical Research Centre funding brings together academics and doctors to translate advances in biomedical research into benefits for patients and the health system and support partnerships between universities and NHS hospitals to drive innovation in the prevention, diagnosis and treatment of ill-health. The new centres also act as a major component of the nation’s knowledge economy, attracting investment from the life sciences industry and making the research environment in England more competitive.
Read our news story on the NIHR Biomedical Research Centres funding competition.
New accredited register for the Clinical Research Practitioner profession
The NIHR announced in June 2021 the launch of a new UK-wide professional accreditation scheme for Clinical Research Practitioners (CRPs) as part of efforts to double the number of this important workforce over the next few years. The aim of introducing this register is to improve professional identity, recognise the vital role CRPs play in research delivery, and provide a clear path for their career development. The standards set are similar to the high levels found in statutory regulation for nursing and other allied health professions. A successful application to the accredited register demonstrates that practitioners meet a defined set of standards and work within an agreed scope of practice.
Read our news story on the Clinical Research Practitioners accreditation scheme.
Thanks to ground-breaking clinical trials, a life-saving anti-cholesterol drug recommended on NHS
A ground-breaking drug to combat heart disease could soon be offered by the NHS, following an innovative programme of clinical trials delivered by the NIHR Clinical Research Network. The National Institute for Health and Care Excellence (NICE) recommended in September 2021 that inclisiran, a treatment to lower cholesterol, should be offered to patients who have already had a stroke or heart attack and are not responding to other cholesterol-lowering treatments. The drug would be delivered as a twice-yearly injection to eligible patients with prior experience of heart attack or stroke, potentially replacing the need to take statins daily while saving thousands of lives a year.
Read our news story on an anti-cholesterol drug trial.
New funding boost for delivery of early-stage clinical research across England
In February 2022, we announced nearly £161 million to fund 28 NIHR Clinical Research Facilities (CRFs), expanding the delivery of early phase clinical research in NHS hospitals across England. These facilities support the delivery of early translational and experimental medicine research, from studies testing new treatments in patients for the very first time (first-in-human trials) to early safety and efficacy trials (Phase IIa trials). A total of 28 NIHR CRFs were awarded funding in this latest round, six more than previously, with about half of the funding awarded to NIHR CRFs outside of London, Oxford and Cambridge.
Read our news story on £161m funding boost awarded to NIHR Clinical Research Facilities.
Patients with unexplained chest pain are at an increased risk of suffering a heart attack later in life
NIHR-supported researchers reported in March 2022 that people with unattributed chest pain were at a 15% increased risk of a heart attack in the first year after visiting their GP, with a continued increased risk over the next 10 years. Many of the one million UK adults seeing their GP because of chest pain each year will not receive a diagnosis, and their records will state they have unattributed chest pain. Heart-related chest pain can be difficult for GPs to diagnose because the symptoms may be put down to other commonly associated conditions, and blockages to the smallest blood vessels supplying the heart are too small to see with traditional tests. The researchers now aim to identify common factors in patients who did go on to suffer a heart attack. This information will help GPs identify those patients with unexplained chest pain who are most at risk so they can be offered medication or further support at an earlier stage to reduce likelihood of a future heart attack.
Read our news story on unexplained chest pain.
World-first CJD treatment shows promising early results
Creutzfeldt–Jakob disease (CJD) is a rare and fatal disease that causes brain damage and for which there is currently no licensed treatment. Most patients die within a few months of diagnosis. In March 2022, a first-in-human treatment designed specifically for CJD showed encouraging early results that may contribute to the development of new treatments for other neurodegenerative diseases. Researchers at the NIHR UCLH Biomedical Research Centre developed a monoclonal antibody that was given to six patients with CJD. Given the small number of patients treated, researchers say the findings should be regarded as preliminary and further studies are needed to draw more comprehensive conclusions.
Partnering with patients, service users, carers and communities to improve the relevance, quality and impact of our research
Shaped through collaboration with patients, service users, carers and communities, NIHR’s research is driven by people, who contribute at every stage of the research pathway and play a vital role by volunteering to participate in studies and trials. We always value and recognise people’s contributions, so all perspectives and experiences are heard and acted upon.
NIHR survey reveals public attitudes to health research following coronavirus
A survey commissioned by the NIHR to mark International Clinical Trials Day in May 2021 revealed a significant disconnect exists between people’s perceptions of the importance of coronavirus research, and their understanding of where it happened and who took part. The YouGov survey asked respondents about their understanding of coronavirus research and the role it has played in tackling the pandemic. It showed that most UK adults believed health research played a very (71%) or fairly (19%) important role in the coronavirus pandemic. 29% of respondents said they trusted health research more now than before the pandemic began, and just over a quarter (27%) said they were now more likely to take part in health research. The survey also identified that there are significant generational differences in attitude to coronavirus research across a range of issues.
Read our news story on attitudes to health research following coronavirus.
Participation in NIHR Clinical Research Network studies doubles in pandemic year
NIHR Clinical Research Network (CRN) annual statistics released in July 2021 showed the extraordinary impact the organisation made in delivering vital clinical research during the 2020/21 pandemic. An unprecedented number of participants took part in NIHR CRN-supported studies in the twelve months between April 2020 and March 2021, with participation levels nearly double the previous year. Over this period, a total of 1,390,483 participants enrolled in CRN portfolio studies in England - up from 732,176 in 2019/20.
Read our news story on record breaking participation in research.
NIHR’s next steps for working in partnership with patients and the public
NIHR has long led the way in partnership working with patients and the public to shape and conduct research in health and social care. Jeremy Taylor, NIHR Director for Public Voice, outlined in an article how we plan to build on our work in this area following a series of workshops with the research community and public contributors. Initiatives include developing an improvement programme, for example encouraging the research community to work more inclusively with a diverse range of people and communities, and prioritising public partnerships to build long-term, equitable relationships with communities as the foundation for a shared approach to research.
Read about the NIHR's plans for working with patients and the public.
High numbers of research participants believe their contribution is valued by researchers
Results from the 2020/21 NIHR Clinical Research Network Participant in Research Experience Survey (PRES) published in October 2021 showed that 93% of participants felt the contribution they made to research through taking part was valued by the researchers and study teams. In addition, respondents highlighted the professionalism, knowledge and friendliness of the research teams as contributing to their positive experiences of taking part in research, with 98% of respondents saying they felt they were treated with courtesy and respect; and 94% of respondents said they would consider taking part in research again.
Find out more about the NIHR CRN Participant in Research Experience Survey.
High numbers of patients and public involved in NIHR’s work report a positive experience
Complementing the aforementioned PRES report, a separate survey of public contributors involved in NIHR’s work reported in January 2022 that patients, carers and the public are involved across many different stages of research, and the majority of people report a positive experience. 79% of people involved with the NIHR felt satisfied or very satisfied and respondents welcomed the opportunities to be involved in the NIHR’s work and research, which they felt was important and much needed. In addition, a majority of survey respondents (63%) felt their involvement had made a difference, with a further 19% stating it had sometimes made a difference.
Find out more about the NIHR survey of public contributors.
NIHR unites with health and social care leaders to improve public involvement in research
Funders, regulators and research organisations who play an important role in UK health and social care research came together in March 2022, working with members of the public, to sign up to a bold new shared commitment to improve public involvement in research. The statement was co-produced with members of the public, patients and service users. This shared commitment aims to address the gaps identified in leadership and communication by bringing patients and public contributors and leaders in health and social care together to set out the importance of public involvement in all health and social care research.
Read our news story of our new shared commitment to improve public involvement in research.
Collaborating with other public funders, charities and industry, to shape a cohesive and globally competitive research system
Working in partnership with the public sector, medical research charities and the life sciences industry, NIHR has helped create an integrated research system that both meets the needs of patients and the public and positions the UK as a globally attractive destination for high-quality clinical research.
NIHR partners with Diabetes UK to fund vital research into preventing complications in people with type 2 diabetes
In May 2021, NIHR joined forces with Diabetes UK to fund a new £2.1 million project to prevent cardiovascular disease in people with type 2 diabetes who have had a diabetic foot ulcer. With funding from NIHR Programme Grants for Applied Research and Diabetes UK, Professor Kamlesh Khunti and his team at the University of Leicester are using health records to find out how many people with type 2 diabetes who also have a diabetic foot ulcer will go on to experience heart disease or stroke. The team are also exploring whether factors such as age, ethnicity, socioeconomic status or geographical location might put people at higher risk.
Read our news story on funding vital diabetes research.
New wave of AI technologies in £36 million funding boost
Thousands of patients are set to benefit from artificial intelligence (AI) technologies thanks to £36 million for new research, delivered in partnership with NHSX. Technology that can detect cancer and an app that provides AI mental health support are among 38 newly funded innovations to be tested across the health service to help speed up diagnosis and improve care.
Read our news story on our funding boost for AI technologies.
Strategic partnership to strengthen understanding of nutrition and cancer
Dietary factors play an important role in the prevention, development, treatment and survival of cancer. However, currently, there is a gap in the provision of cancer-related nutritional information for those who need it most. In October 2021, the leading charity World Cancer Research Fund and the NIHR Cancer and Nutrition Collaboration announced a strategic partnership focused on delivering consistent, credible information and training about the links between cancer and diet to a greater number of people, including health professionals, patients and those looking to reduce their risk of cancer.
Read our news story on The NIHR Cancer and Nutrition Collaboration.
UK clinical research ecosystem continues to build on learnings from COVID-19 research
In December 2021, The UK Clinical Research Recovery, Resilience and Growth Programme (RRG) published an update detailing key milestones achieved in the six months since the publication of “The Future of UK Clinical Research Delivery” 2021/22 implementation plan. NIHR, one of the key delivery partners of the RRG Programme, has led and is contributing to several important pieces of work including: leading a managed approach to the recovery of the UK clinical research portfolio; creating more capabilities for the Be Part of Research website; and launching a new UK-wide professional accreditation scheme for Clinical Research Practitioners and an Associate Principal Investigator scheme.
Read our news story on building on learnings from COVID-19 research.
New study explores how pollutants indoors impact child health
Pollutants from wood-burning stoves, clothing, cleaning products and cooking can build up indoors, especially over winter, alongside outdoor pollution such as traffic fumes. In the UK, people spend on average 90% of their time indoors, so research in this area is key to understanding the connection between pollution and human health. To investigate this, NIHR announced in March 2022 that it is co-funding a major new study with UK Research and Innovation (UKRI) to discover how everyday pollutants impact the development and health of foetuses and children called RESPIRE. This will be the first to track how the function of different organs such as the lungs and brain are impacted by pollution in the home, work or other indoor places we visit.
Read our news story on indoor pollutants and child health.
Competition to develop new Clinician Researcher development programmes
In April 2021 NIHR, in partnership with the Academy of Medical Royal Colleges (AoMRC), invited Higher Education Institutions to apply for funding to develop a Postgraduate Certificate focused on the practical elements of clinical research. This qualification forms part of the new NIHR-AoMRC Clinician Researcher Credentials Framework will provide clinicians with the necessary knowledge, skills and confidence to begin to contribute to, and develop towards leading, clinical research locally. The introduction of these credentials will increase the capacity for research across the workforce and enable the NHS to deliver high-quality clinical research in everyday clinical settings.
Funding applied global health research and training, to meet the needs of the poorest people in low and middle-income countries
NIHR works closely with the global health research community, funding applied research and training to benefit the poorest people in more than 50 low and middle-income countries (LMICs). Sharing our learning and knowledge enables us to build research and development capacity and capability in both the UK and LMICs.
Life-changing research study led by African midwives is helping reduce stillbirths
Globally, 2 million stillbirths occur every year. Sub-Saharan Africa accounts for 64% of these, with women eight times more likely to experience a stillbirth than those in high-income countries like the UK. A life-changing four-year research programme, funded by the NIHR’s Global Health Research Programme, is helping to tackle the stillbirth crisis in sub-Saharan Africa. The NIHR Global Health Group on Stillbirth Prevention and Management in Sub-Saharan Africa, established in 2017, is the first programme of its kind aimed at reducing stillbirths. This midwife-led research partnership aims to address a critical lack of research around stillbirth, identify best practices, and support for families who endure stillbirths in Kenya, Malawi, Uganda, Tanzania, Zambia and Zimbabwe
Read our news story on how research led by African midwives is reducing stillbirths.
UK and Canada team up to support youth mental health projects worldwide
The COVID-19 pandemic has increased mental health challenges worldwide, yet only 0.1% of global development assistance for health goes towards youth mental health. In April 2021, NIHR announced that it has teamed up with partners in the Global Mental Health Program to launch the first cohort of 18 seed projects to address mental health literacy and provide youth-friendly services for under-served young people aged 10 to 24, in low and middle-income countries. The 18 innovative projects will enhance community-based mental health care for young people in 14 countries: India, Uganda, Kyrgyzstan, Ukraine, Kazakhstan, Iraq, Kenya, Colombia, Lebanon, Democratic Republic of Congo, Mexico, Cameroon, Nigeria and Rwanda.
Read our news story on supporting youth mental health projects worldwide.
One-stop clinics for HIV, diabetes and hypertension care cut patient health costs in Africa
The burden of non-communicable diseases has risen rapidly in Africa. Integrating the care of HIV, diabetes, and hypertension into a ‘one-stop clinic’ can reduce the costs for both patients and healthcare services, according to a new NIHR-funded global health research study published in September 2021 in BMC Medicine. The research team from the NIHR Global Health Research Group on prevention and management of non-communicable diseases and HIV-infection in Africa, (RESPOND-Africa consortium) led by The Liverpool School for Tropical Medicine with partners in Tanzania and Uganda, found that integrating these services with existing high-quality HIV care services has resulted in greatly improved patient outcomes and cost savings.
Read our news story on one-stop clinics in Africa.
One in seven cancer patients around the world have missed out on potentially life-saving operations during COVID-19 lockdowns
In April 2021, a new study reported that planned cancer surgery was affected by lockdowns regardless of the local COVID-19 rates at that time, with patients in lower-income countries at the highest risk of missing their surgery. Data was analysed from the 15 most common solid cancer types in 20,000 patients across 466 hospitals in 61 countries. It found that patients awaiting surgery for more than six weeks during full lockdown were significantly less likely to have their planned cancer surgery. Frail patients, those with advanced cancer, and those waiting for surgery in low and middle-income countries were all less likely to have the cancer operation they urgently needed. The study was funded by the NIHR Global Health Research Programme and published in The Lancet Oncology.
Read our news story on cancer patients missing life-saving operations due to COVID-19 lockdowns.
New research could help boost the growth of clean cooking in sub-Saharan Africa
NIHR-funded researchers from the NIHR CLEAN-Air (Africa) Global Health Research Group based at the University of Liverpool have produced new evidence that could help rapidly boost efforts to scale up the adoption of clean cooking with liquefied petroleum gas (LPG) in sub-Saharan Africa. Published in November 2021 in Nature Energy, this new study suggests that supply-side interventions such as shortening the distance to LPG retail points and improving access to multi-burner LPG stoves could help increase the consumption of clean cooking fuels compared to higher polluting fuels such as charcoal and firewood, for the benefit of public health, gender equality and environmental protection.
Read our news story on research helping the adoption of clean cooking in Africa.
£19.3 million announced to fund global health research into multiple long-term conditions
In November 2021, NIHR awarded nearly £20 million through its global health funding programme to help tackle multiple long-term conditions. The awards, made through the NIHR's Research and Innovation for Global Health Transformation programme, will be shared between four projects that will examine clusters of chronic conditions that represent a significant disease burden in low and middle-income countries. Research will take place in Pakistan and sub-Saharan Africa. These chronic conditions can particularly affect children and adolescents in these countries due to the effects of poverty, hunger and infectious diseases.
Read our news story on new Global Health Research funding for multiple long-term conditions.
Financial summary - 2021/22
NIHR spend increased by around 8% in 2021/22 from 2020/21, largely due to additional funding secured at the Spending Review in 2020. This allowed NIHR to make additional investments in faculty, programmes and infrastructure, as well as investing over £10m in a cross-NIHR digital strategy.
NIHR continued to invest heavily in research into COVID-19, with £92m spent on a range of studies, many in partnership with UKRI.
The Vaccines Task Force continued to support NIHR research into COVID-19, providing over £45m of additional budget.
Research Programmes | Spend (£m) 2021/22 |
---|---|
AI (including AI i4i and AI Multiple long term conditions call) | 14.0 |
Efficacy and Mechanism Evaluation | 18.6 |
Excess treatment cost funding (part-funded by NHS England) | 6.6 |
Health Protection Research Units | 10.7 |
Health Services Delivery & Research | 29.8 |
Health Technology Assessment - Commissioned | 40.0 |
Health Technology Assessment - Researcher Led | 36.7 |
Health Technology Assessment - Themed | 18.2 |
Invention for Innovation | 23.6 |
INVOLVE/Centre for Engagement and Dissemination | 2.7 |
NHS Blood and Transplant Units | 3.5 |
NIHR Innovation Observatory | 2.1 |
Policy Research Programme | 31.2 |
Programme Grants for Applied Research | 39.4 |
Public Health Research | 23.6 |
Research Capability Funding | 51.0 |
Research for Patient Benefit | 19.8 |
Schools: Primary Care, Public Health and Social Care Research | 15.7 |
Systematic Reviews (Cochrane and TARs) | 13.2 |
Other, including legacy programmes and management not attributed to specific programmes | 26.5 |
Contributions to UKRI research programmes | Spend (£m) 2021/22 |
---|---|
ESRC-NIHR Dementia Research Initiative | 2.9 |
MRC-NIHR Tackling Multimorbidity at Scale Initiative | 2.1 |
MRC-NIHR Methodology Research Programme | 1.0 |
Other contributions to UKRI research programmes | 0.6 |
Infrastructure | Spend (£m) 2021/22 |
---|---|
Applied Research Collaborations | 34.8 |
Biomedical Research Centres | 181.3 |
Clinical Research Facilities | 23.9 |
Clinical Research Network | 358.0 |
Clinical Trials Unit Support Funding | 3.3 |
Experimental Cancer Medicine Centres | 3.3 |
Medtech and In-vitro Diagnostics Cooperatives | 3.4 |
Patient Safety Translational Research Centres | 3.5 |
Research Design Service | 11.7 |
Other (including management) | 8.9 |
Infrastructure total | 632.0 |
Faculty | Spend (£m) 2021/22 |
---|---|
70@70 Senior Nurse and Midwife Research Leader Programme | 1.9 |
Academic Clinical Fellows | 42.7 |
Academy Fellowships (including legacy training awards) | 33.5 |
Clinical Academic Research Partnerships (via UKRI) | 1.2 |
Clinical Lectureships | 23.4 |
Research Professorships | 7.5 |
Senior Investigators | 3.2 |
Other (including management and clinical academics) | 7.2 |
Faculty total | 120.7 |
Systems | Spend (£m) 2021/22 |
---|---|
Information systems that enable research | 11.9 |
Knowledge services and data | 1.4 |
Systems total | 13.3 |
COVID-19 | Spend (£m) 2021/22 |
---|---|
COVID-19 studies (including those funded by the Vaccines Task Force and delivered through UKRI) | 92.0 |
COVID-19 total | 92.0 |
Total NIHR spend excluding Official Development Assistance (£m) £1,259.4
Official Development Assistance (ODA) | Spend (£m) 2021/22 |
---|---|
Antimicrobial Resistance (AMR) Operational Research (World Health Organization TDR Partnership) | 2.1 |
Early Career Grants Scheme (Royal Society of Tropical Medicine and Hygiene Partnership) | 0.8 |
European and Developing Countries Clinical Trials Partnership - Phase II | 1.8 |
Global Alliance for Chronic Disease (Medical Research Council Partnership) | 1.0 |
Global Effort on COVID-19 (GECO) Health Research (Medical Research Council Partnership) | 5.2 |
Global Maternal and Neonatal Health (Medical Research Council Partnership) | 1.1 |
Global Mental Health Partnership (Grand Challenges Canada Partnership) | 3.3 |
Joint Global Health Trials Initiative (Medical Research Council, Wellcome and FCDO Partnership) | 4.7 |
NIHR Global Health Policy and Systems Research Programme | 2.2 |
NIHR Global Health Research Groups | 16.7 |
NIHR Global Health Research Units | 9.4 |
NIHR Global Research Professorships | 2.1 |
NIHR Research and Innovation for Global Health Transformation | 7.9 |
NIHR-Wellcome Partnership on Major Awards, International Fellowships and Research to Policy Uptake Initiative | 3.9 |
Research for Adolescent Health in Low and Middle Income Countries (Medical Research Council Partnership) | 2.0 |
Research for Health in Humanitarian Crisis (Elrha Partnership) | 0.5 |
Other | 0.4 |
Total ODA | 65.0 |
Total NIHR spend including Official Development Assistance (£m) £1,324.4
Please note the figures in the financial summary are provisional and are unaudited